Medical devices and software services provider Body Vision Medical has raised $8.5m through a financing round led by the company’s chairman Zohar Gilon.
The company plans to use the funds towards the commercialisation of its LungVision™ system in the US and towards the expansion of its product pipeline.
The FDA-approved LungVision™ system is an imaging device used in conjunction with standard bronchoscopes for real-time diagnosis.
Attune Medical has closed series C financing by raising funds of more than $15.5m.
Funds will be used towards the expansion of the company’s technology into clinical applications such as prevention of hypothermia during operating room procedures and to support the global adoption of its oesophageal temperature management device, EnsoETM.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Based in the US, Attune Medical is a medical device company involved in the development of temperature management devices.
Miracor Medical SA (Miracor Medical) has raised series D financing of €30m ($34.8m) from Ming Capital, an investor based in China.
The funding round also saw the participation of new investors, including Belgian investment firm Quest for Growth and existing investors Ming Capital, SFPI, and Meusinvest.
The company plans to use the funds to support clinical development and for the commercialisation of the PiCSO® Impulse System.
PiCSO® is a coronary sinus occlusion system, which uses a balloon catheter inserted into the coronary sinus. It is designed to reduce infarct size in patients suffering from acute myocardial infarct.
Based in the US, Miracor Medical is a medical device company that provides innovative solutions for the treatment of severe cardiac diseases.
AIT Therapeutics Inc has sold 177,000 unregistered shares of its common stock priced at $4.50 a share to US-based investment firm Lincoln Park Capital Fund LLC (LPC).
The company plans to sell the balance of $20m-worth shares over a 36-month period to LPC.
AIT plans to use the funds towards the ongoing development of its ventilator-compatible NO Generator and Delivery System and to carry out pivotal studies in bronchiolitis and lung infections.
Based in the US, AIT Therapeutics is a clinical-stage medical device company that uses nitric oxide (NO) to treat respiratory and other diseases.